Cargando…

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib

Advances in our understanding of renal cancer biology have led to a new treatment paradigm in renal cancer. Tyrosine kinase inhibitors (TKI), that target the intracellular kinase domain of the VEGF receptor, have become established as the most successful class of agent in this disease. Three TKIs ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasudev, Naveen S., Larkin, James M.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210627/
https://www.ncbi.nlm.nih.gov/pubmed/22084622
http://dx.doi.org/10.4137/CMO.S7263
_version_ 1782215750431277056
author Vasudev, Naveen S.
Larkin, James M.G.
author_facet Vasudev, Naveen S.
Larkin, James M.G.
author_sort Vasudev, Naveen S.
collection PubMed
description Advances in our understanding of renal cancer biology have led to a new treatment paradigm in renal cancer. Tyrosine kinase inhibitors (TKI), that target the intracellular kinase domain of the VEGF receptor, have become established as the most successful class of agent in this disease. Three TKIs are currently approved for use in patients with advanced disease. Newer, more potent inhibitors have reached phase III clinical testing, meaning others are likely to follow. In 2009, pazopanib became the most recent TKI to receive FDA approval. This review sets out to discuss the key opportunities and challenges associated with TKI use in RCC, focusing particularly on pazopanib. We also review the current place of pazopanib in the management of patients with advanced disease, in what is a rapidly evolving therapeutic landscape.
format Online
Article
Text
id pubmed-3210627
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-32106272011-11-14 Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib Vasudev, Naveen S. Larkin, James M.G. Clin Med Insights Oncol Review Advances in our understanding of renal cancer biology have led to a new treatment paradigm in renal cancer. Tyrosine kinase inhibitors (TKI), that target the intracellular kinase domain of the VEGF receptor, have become established as the most successful class of agent in this disease. Three TKIs are currently approved for use in patients with advanced disease. Newer, more potent inhibitors have reached phase III clinical testing, meaning others are likely to follow. In 2009, pazopanib became the most recent TKI to receive FDA approval. This review sets out to discuss the key opportunities and challenges associated with TKI use in RCC, focusing particularly on pazopanib. We also review the current place of pazopanib in the management of patients with advanced disease, in what is a rapidly evolving therapeutic landscape. Libertas Academica 2011-10-31 /pmc/articles/PMC3210627/ /pubmed/22084622 http://dx.doi.org/10.4137/CMO.S7263 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Vasudev, Naveen S.
Larkin, James M.G.
Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
title Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
title_full Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
title_fullStr Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
title_full_unstemmed Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
title_short Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
title_sort tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210627/
https://www.ncbi.nlm.nih.gov/pubmed/22084622
http://dx.doi.org/10.4137/CMO.S7263
work_keys_str_mv AT vasudevnaveens tyrosinekinaseinhibitorsinthetreatmentofadvancedrenalcellcarcinomafocusonpazopanib
AT larkinjamesmg tyrosinekinaseinhibitorsinthetreatmentofadvancedrenalcellcarcinomafocusonpazopanib